Naltrexone/Bupropion Cardiovascular Outcomes Study

NCT02638129 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

67

Enrollment

INDUSTRY

Sponsor class

Conditions

Obesity
Cardiovascular Diseases

Interventions

DRUG: Naltrexone HCl/Bupropion HCl ER
DRUG: Placebo

Sponsor

Orexigen Therapeutics, Inc